YIBAI PHARMACEUTICAL(SH:600594) Xin Lang Cai Jing·2025-08-21 01:37Core Viewpoint - Yibai Pharmaceutical (600594.SH) reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1][3]. Financial Performance - The company's total revenue for the first half of 2025 was 993 million yuan, a decrease of 175 million yuan compared to the same period last year, representing a year-on-year decline of 14.99% [1]. - The net profit attributable to shareholders was -19.90 million yuan, indicating a loss [1]. - Operating cash flow showed a net inflow of 171 million yuan, down by 32.54 million yuan from the same period last year, a decline of 16.02% year-on-year [1]. Profitability and Efficiency Metrics - The latest asset-liability ratio stood at 36.24%, an increase of 1.19 percentage points from the previous quarter and up 1.04 percentage points from the same period last year [3]. - The gross profit margin was reported at 60.65%, down by 1.79 percentage points compared to the previous year [3]. - The return on equity (ROE) was -0.81%, indicating negative returns for shareholders [3]. - The diluted earnings per share were -0.03 yuan [4]. - The total asset turnover ratio was 0.24 times, a decrease of 0.02 times year-on-year, reflecting a decline of 6.09% [4]. - The inventory turnover ratio was 0.66 times, down by 0.08 times from the previous year, representing a decline of 10.26% [4]. Shareholder Structure - The number of shareholders was reported at 46,200, with the top ten shareholders holding a total of 260 million shares, accounting for 32.83% of the total share capital [4]. - The largest shareholder, Dou Qiling, held 23.42% of the shares [4].